Lai Lana Y H, Petrone Andrew B, Pankow James S, Arnett Donna K, North Kari E, Ellison R Curtis, Hunt Steven C, Rosenzweig James L, Djoussé Luc
School of Medicine, Boston University, 72, East Concord St, Boston, MA, USA.
Clinical Research Center, Sarawak General Hospital, Kuching, Malaysia.
Diabetes Metab Res Rev. 2015 Sep;31(6):582-7. doi: 10.1002/dmrr.2638. Epub 2015 Apr 6.
Metabolic syndrome (MetS), characterized by abdominal obesity, atherogenic dyslipidaemia, elevated blood pressure and insulin resistance, is a major public health concern in the United States. The effects of apolipoprotein E (Apo E) polymorphism on MetS are not well established.
We conducted a cross-sectional study consisting of 1551 participants from the National Heart, Lung and Blood Institute Family Heart Study to assess the relation of Apo E polymorphism with the prevalence of MetS. MetS was defined according to the American Heart Association-National Heart, Lung and Blood Institute-International Diabetes Federation-World Health Organization harmonized criteria. We used generalized estimating equations to estimate adjusted odds ratios (ORs) for prevalent MetS and the Bonferroni correction to account for multiple testing in the secondary analysis.
Our study population had a mean age (standard deviation) of 56.5 (11.0) years, and 49.7% had MetS. There was no association between the Apo E genotypes and the MetS. The multivariable adjusted ORs (95% confidence interval) were 1.00 (reference), 1.26 (0.31-5.21), 0.89 (0.62-1.29), 1.13 (0.61-2.10), 1.13 (0.88-1.47) and 1.87 (0.91-3.85) for the Ɛ3/Ɛ3, Ɛ2/Ɛ2, Ɛ2/Ɛ3, Ɛ2/Ɛ4, Ɛ3/Ɛ4 and Ɛ4/Ɛ4 genotypes, respectively. In a secondary analysis, Ɛ2/Ɛ3 genotype was associated with 41% lower prevalence odds of low high-density lipoprotein [multivariable adjusted ORs (95% confidence interval) = 0.59 (0.36-0.95)] compared with Ɛ3/Ɛ3 genotype.
Our findings do not support an association between Apo E polymorphism and MetS in a multicentre population-based study of predominantly White US men and women.
代谢综合征（MetS）以腹型肥胖、致动脉粥样硬化性血脂异常、血压升高和胰岛素抵抗为特征，是美国主要的公共卫生问题。载脂蛋白E（Apo E）基因多态性对代谢综合征的影响尚未完全明确。
我们进行了一项横断面研究，纳入了来自美国国立心肺血液研究所家庭心脏研究的1551名参与者，以评估Apo E基因多态性与代谢综合征患病率之间的关系。代谢综合征根据美国心脏协会-美国国立心肺血液研究所-国际糖尿病联盟-世界卫生组织统一标准进行定义。我们使用广义估计方程来估计代谢综合征患病率的调整比值比（OR），并在二次分析中采用Bonferroni校正来处理多重检验。
我们的研究人群平均年龄（标准差）为56.5（11.0）岁，49.7%的人患有代谢综合征。Apo E基因分型与代谢综合征之间无关联。对于ε3/ε3、ε2/ε2、ε2/ε3、ε2/ε4、ε3/ε4和ε4/ε4基因型，多变量调整后的OR（95%置信区间）分别为1.00（参考值）、1.26（0.31 - 5.21）、0.89（0.62 - 1.29）、1.13（0.61 - 2.10）、1.13（0.88 - 1.47）和1.87（0.91 - 3.85）。在二次分析中，与ε3/ε3基因型相比，ε2/ε3基因型与低高密度脂蛋白患病率低41%相关[多变量调整后的OR（95%置信区间）= 0.59（0.36 - 0.95）]。
在一项以美国白种人为主的多中心人群研究中，我们的研究结果不支持Apo E基因多态性与代谢综合征之间存在关联。
